Tolerability profiles of rofecoxib (Vioxx®) and Arthrotec®: A comparison of six weeks treatment in patients with osteoarthritis

Reference

• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888–99.
   PubMed Web of Science ®Google Scholar
• McCarthy DM. Comparative toxicity of nonsteroidal anti-inflammatory drugs. Am J Med 1999;107:37–47.
   PubMedGoogle Scholar
• Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastro-intestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995;123:241–9.
   PubMed Web of Science ®Google Scholar
• Langman MJS, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075–8.
   PubMed Web of Science ®Google Scholar
• Singh G, Ramey DR. NSAID induced gastrointestinal complications: the ARAMIS perspective 1997. J Rheumatol 1998;25:8–16.
   Web of Science ®Google Scholar
• Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992;327:749–54.
   Google Scholar
• Bjorkman DJ. Current status of nonsteroidal anti-inflamma-tory drug (NSAID) use in the United States: risk factors and frequency of complications. Am J Med 1999;107:3–10.
   PubMedGoogle Scholar
• Hawkey CJ. Progress in prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions. Omepra-zole NSAID Steering Committee. Am J Med 1998;104:67–74.
   Google Scholar
• Scheiman J, Isenberg J. Agents used in the prevention and treatment of nonsteroidal anti-inflammatory drug-associated symptoms and ulcers. Am J Med 1998;105:32–8.
   Google Scholar
• Morrison BW, Christensen S, Yuan W, Brown J, Amlani S, Seidenberg B. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther 1999;21:943–53.
   PubMed Web of Science ®Google Scholar
• Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year randomized clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000;43:978–87.
   PubMed Web of Science ®Google Scholar
• LaMe L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776–83.
   PubMed Web of Science ®Google Scholar
• Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clinical Pharmacol Ther 1999;65:336–47.
   Google Scholar
• Lanza FL, Rack ML, Simon TJ. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999;13: 761–7.
   Google Scholar
• Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, et al. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsul-fonylpheny1)-3-pheny1-2-5H -furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and bio-chemical profiles. J Pharmacol Exp Ther 1999;290:551–60.
   PubMed Web of Science ®Google Scholar
• Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160: 1781–7.
   Google Scholar
• Langman MJ, Jensen DM, Watson DJ, Harper S, Zhao PL, Quan H, et al. Incidence of upper gastrointestinal perfora-tions, symptomatic ulcers, and bleeding (PUBs): Rofecoxib compared to NSAIDs. JAMA 1999;282:1929–33.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q, et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clinical Therapeutics 1999;21:1688–1702.
   PubMed Web of Science ®Google Scholar
• Morrison BW, Daniels SE, Kotey P, Cantu N, Seidenberg B. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 1999;94: 504–8.
   Google Scholar
• Hawkey C, LaMe L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al. Comparison of the effect of rofecoxib a cyclooxygenase 2 inhibitor, ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, controlled, double-blind, placebo-controlled trial. Arthritis Rheum 2000;43: 370–7.
   Google Scholar
• Sigthrosson G, Crane R, Simon T, Hoover M, Quan H, Bolognese J, et al. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double-blind, crossover study comparing rofecoxib with placebo and indomethacin. GUT 2000;47:527–32.
   PubMedGoogle Scholar
• Hunt RH, Bowen B, Mortensen ER, Simon TJ, James C, Cagliola A, et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med 2000;109:201–6.
   PubMed Web of Science ®Google Scholar
• McKenna F. DiclofenadMisoprostol: the European clinical experience. J Rheumatol 1998;25 Suppl. 51:21–30.
   Google Scholar
• Bellamy N. Outcome measurement in osteoarthritis clinical trials. J Rheumatol 1995;22:49–51.
   Google Scholar
• Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with non-selective COX- 1 /C0X-2 inhibitors in osteoarthritis. Archives Intern Med 2000;160:2998–3003.
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell J, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiin-flammatory drugs. N Engl J Med 1998;338:727–34.
   PubMed Web of Science ®Google Scholar
• Levy RL, Feld AD. Increasing patient adherence to gastro-enterology treatment and prevention regimens. Amer J Gastro 1999;94:1733–42.
   PubMed Web of Science ®Google Scholar
• Haynes RB, McKibbon KA, Kanani R. Systematic review of randomized trials of intervention to assist patients to follow prescriptions for medications. Lancet 1996;348:383–6.
   Google Scholar
• de Pouvourville G. The iatrogenic cost of non-steroidal anti-inflammatory drug therapy. Br J Rheumatol 1995b;34 Suppl. 1:19–24.
   Google Scholar
• Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier L. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetamino-phen: Retrospective cohort study of an elderly population. Arthritis Rheum 2000;43:917–24.
   Google Scholar
• Maetzel A, Bosi Ferraz M, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointest-inal events associated with the use of nonsteroidal antiin-flammatory drugs. Arthritis Rheum 1998;41:16–25.
   PubMed Web of Science ®Google Scholar
• Blower AL, Brooks A, Fenn GC, Hill A, Pearce MY, Morant S, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997;11:283–91.
   PubMed Web of Science ®Google Scholar
• Moore N, Montout C, Verschuren X, Callens J, Kong SX, Bégaud B. Use of gastrointestinal (GI) protective agents among patients on non-steroidal anti-inflammatory drugs in France. Pharmacoepidemiol Drug Safety 1999;8 Suppl 2: S139 (in Soc. Proc.).
   Google Scholar
• Singh G. Recent considerations in nonsteroidal anti-inflam-matory drug gastropathy. Am J Med 1998;105:31–8.
   PubMedGoogle Scholar
• Schnitzer TJ, Kong SX, Kahler KH, Watson DJ, Straus WL. NSAID prescription patterns and use of gastroprotective agents: a cohort analysis of a U.S. prescription database. Ann Rheum Dis 2000;59 Suppl I:278.
   Google Scholar